Research Overview


Our laboratory combines traditional neuropathology methods with quantitative approaches to advance brain science in the areas of brain aging, cancer, neurotrauma, and neurodegenerative disease. 


Rapid Brain Removal & Brain Autopsy

Timely acquisition and preservation of brain and spinal cord tissue is essential to the Keene lab’s research and tissue sharing efforts. Our dedicated brain removal and autopsy team facilitates the generous gifts of over 200 donors each year in addition to maintaining a biorepository of fresh frozen and formalin-fixed specimens from thousands of subjects.


Ex-Vivo MRI & 3D Image Reconstructions

Ex-vivo MRI of fixed brain tissue, led by UW Professor of Neurological Surgery Dr. Christine Mac Donald, provides an important tool to guide regional sampling for neuropathologic evaluation and measure volumes of diverse structures across the brain. Combined with MRI imaging taken at various time points in a subject’s life, ex-vivo MRI enables us to study how symptoms of disease progression may correlate with changes in brain size. Leveraging sophisticated imaging software, the BRaIN lab also generates 3D image reconstructions of the whole brain from photos taken of individual brain slices at the time of autopsy.


Neurohistology & Neuropathological Diagnostics

Our fixed research tissue samples are transformed into paraffin-embedded blocks and receive complete neurohistologic work-up, enabling board-certified neuropathologists to provide family members with definitive neuropathological diagnoses and an explanation of symptoms for their loved ones. The BRaIN lab performs immunohistochemical staining for a wide array of markers related to various neurodegenerative processes, aiming to understand the pathologic correlates of brain disease. 


Quantitative Neuropathology

While consensus criteria for the neuropathologic diagnosis of Alzheimer’s disease (AD) rely on ordered rankings of amyloid plaque and neurofibrillary tangle distribution across the brain, these non-quantitative measures have limited utility in correlating pathological features of AD with parameters like age, gender, exposures, genotype, comorbid processes and environmental factors. To provide more robust correlative power, the BRaIN lab performs high-throughput, multiplexed quantitative assays to measure levels of amyloid beta, tau and other toxic proteins across the brain in large patient cohorts. In addition, we leverage AI-driven, high-resolution digital image analysis tools to quantify the distribution and amount of pathology on immunostained slides. These complementary quantitative approaches afford an in-depth view into the molecular drivers of disease.